Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML

NCT01411267 is registered in ClinicalTrials.gov with Therapeutic Advances in Childhood Leukemia Consortium as lead sponsor.

NCT NCT01411267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01411267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Phase
Phase 1
Overall status
Completed
Start date
September 1, 2011
Completion date
September 12, 2013
Enrollment
24 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoblastic leukemia, acute, childhood, myelogenous leukemia, acute, childhood